These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 27878989)

  • 1. Discovery and biological characterization of potent myeloid cell leukemia-1 inhibitors.
    Lee T; Bian Z; Zhao B; Hogdal LJ; Sensintaffar JL; Goodwin CM; Belmar J; Shaw S; Tarr JC; Veerasamy N; Matulis SM; Koss B; Fischer MA; Arnold AL; Camper DV; Browning CF; Rossanese OW; Budhraja A; Opferman J; Boise LH; Savona MR; Letai A; Olejniczak ET; Fesik SW
    FEBS Lett; 2017 Jan; 591(1):240-251. PubMed ID: 27878989
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Optimization of Potent and Selective Tricyclic Indole Diazepinone Myeloid Cell Leukemia-1 Inhibitors Using Structure-Based Design.
    Shaw S; Bian Z; Zhao B; Tarr JC; Veerasamy N; Jeon KO; Belmar J; Arnold AL; Fogarty SA; Perry E; Sensintaffar JL; Camper DV; Rossanese OW; Lee T; Olejniczak ET; Fesik SW
    J Med Chem; 2018 Mar; 61(6):2410-2421. PubMed ID: 29323899
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Myeloid cell leukemia-1 is an important apoptotic survival factor in triple-negative breast cancer.
    Goodwin CM; Rossanese OW; Olejniczak ET; Fesik SW
    Cell Death Differ; 2015 Dec; 22(12):2098-106. PubMed ID: 26045046
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Discovery of Potent Myeloid Cell Leukemia-1 (Mcl-1) Inhibitors That Demonstrate in Vivo Activity in Mouse Xenograft Models of Human Cancer.
    Lee T; Christov PP; Shaw S; Tarr JC; Zhao B; Veerasamy N; Jeon KO; Mills JJ; Bian Z; Sensintaffar JL; Arnold AL; Fogarty SA; Perry E; Ramsey HE; Cook RS; Hollingshead M; Davis Millin M; Lee KM; Koss B; Budhraja A; Opferman JT; Kim K; Arteaga CL; Moore WJ; Olejniczak ET; Savona MR; Fesik SW
    J Med Chem; 2019 Apr; 62(8):3971-3988. PubMed ID: 30929420
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Molecular analysis of functional redundancy among anti-apoptotic Bcl-2 proteins and its role in cancer cell survival.
    Eichhorn JM; Alford SE; Sakurikar N; Chambers TC
    Exp Cell Res; 2014 Apr; 322(2):415-24. PubMed ID: 24556425
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Discovery of S64315, a Potent and Selective Mcl-1 Inhibitor.
    Szlavik Z; Csekei M; Paczal A; Szabo ZB; Sipos S; Radics G; Proszenyak A; Balint B; Murray J; Davidson J; Chen I; Dokurno P; Surgenor AE; Daniels ZM; Hubbard RE; Le Toumelin-Braizat G; Claperon A; Lysiak-Auvity G; Girard AM; Bruno A; Chanrion M; Colland F; Maragno AL; Demarles D; Geneste O; Kotschy A
    J Med Chem; 2020 Nov; 63(22):13762-13795. PubMed ID: 33146521
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Structure-based virtual screening, biological evaluation and biophysical study of novel Mcl-1 inhibitors.
    Du J; Liu L; Liu B; Yang J; Hou X; Yu J; Fang H
    Future Med Chem; 2020 Jul; 12(14):1293-1304. PubMed ID: 32397829
    [No Abstract]   [Full Text] [Related]  

  • 8. Recent Advances in Cancer Drug Development: Targeting Induced Myeloid Cell Leukemia-1 (Mcl-1) Differentiation Protein.
    Abid M; Sonawane YA; Contreras JI; Rana S; Natarajan A
    Curr Med Chem; 2017; 24(40):4488-4514. PubMed ID: 28901269
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibition of Mcl-1 with the pan-Bcl-2 family inhibitor (-)BI97D6 overcomes ABT-737 resistance in acute myeloid leukemia.
    Pan R; Ruvolo VR; Wei J; Konopleva M; Reed JC; Pellecchia M; Andreeff M; Ruvolo PP
    Blood; 2015 Jul; 126(3):363-72. PubMed ID: 26045609
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Discovery of potent myeloid cell leukemia 1 (Mcl-1) inhibitors using fragment-based methods and structure-based design.
    Friberg A; Vigil D; Zhao B; Daniels RN; Burke JP; Garcia-Barrantes PM; Camper D; Chauder BA; Lee T; Olejniczak ET; Fesik SW
    J Med Chem; 2013 Jan; 56(1):15-30. PubMed ID: 23244564
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Small molecule Mcl-1 inhibitors for the treatment of cancer.
    Belmar J; Fesik SW
    Pharmacol Ther; 2015 Jan; 145():76-84. PubMed ID: 25172548
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Drimane Derivatives as the First Examples of Covalent BH3 Mimetics that Target MCL-1.
    Daressy F; Malard F; Seguy L; Guérineau V; Apel C; Dumontet V; Robert A; Groo AC; Litaudon M; Bignon J; Desrat S; Malzert-Fréon A; Wiels J; Lescop E; Roussi F
    ChemMedChem; 2021 Jun; 16(11):1788-1797. PubMed ID: 33665938
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Design, synthesis and preliminary biological studies of pyrrolidine derivatives as Mcl-1 inhibitors.
    Wan Y; Wang J; Sun F; Chen M; Hou X; Fang H
    Bioorg Med Chem; 2015 Dec; 23(24):7685-93. PubMed ID: 26620718
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Small-molecule Mcl-1 inhibitors: Emerging anti-tumor agents.
    Wan Y; Dai N; Tang Z; Fang H
    Eur J Med Chem; 2018 Feb; 146():471-482. PubMed ID: 29407973
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hydroxyquinoline-derived compounds and analoguing of selective Mcl-1 inhibitors using a functional biomarker.
    Richard DJ; Lena R; Bannister T; Blake N; Pierceall WE; Carlson NE; Keller CE; Koenig M; He Y; Minond D; Mishra J; Cameron M; Spicer T; Hodder P; Cardone MH
    Bioorg Med Chem; 2013 Nov; 21(21):6642-9. PubMed ID: 23993674
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pyoluteorin derivatives induce Mcl-1 degradation and apoptosis in hematological cancer cells.
    Doi K; Gowda K; Liu Q; Lin JM; Sung SS; Dower C; Claxton D; Loughran TP; Amin S; Wang HG
    Cancer Biol Ther; 2014; 15(12):1688-99. PubMed ID: 25535900
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Discovery of novel indazole-acylsulfonamide hybrids as selective Mcl-1 inhibitors.
    Wan Y; Li Y; Yan C; Wen J; Tang Z
    Bioorg Chem; 2020 Nov; 104():104217. PubMed ID: 32911192
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification of Small-Molecule Inhibitors of the Antiapoptotic Protein Myeloid Cell Leukaemia-1 (Mcl-1).
    Beekman AM; O'Connell MA; Howell LA
    ChemMedChem; 2016 Apr; 11(8):840-4. PubMed ID: 26616140
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Discovery of tricyclic indoles that potently inhibit Mcl-1 using fragment-based methods and structure-based design.
    Burke JP; Bian Z; Shaw S; Zhao B; Goodwin CM; Belmar J; Browning CF; Vigil D; Friberg A; Camper DV; Rossanese OW; Lee T; Olejniczak ET; Fesik SW
    J Med Chem; 2015 May; 58(9):3794-805. PubMed ID: 25844895
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Design, synthesis and biological evaluation of tyrosine derivatives as Mcl-1 inhibitors.
    Liu L; Liu R; Yang X; Hou X; Fang H
    Eur J Med Chem; 2020 Apr; 191():112142. PubMed ID: 32088497
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.